28th Feb 2014 15:59
LONDON (Alliance News) - IXICO PLC, the company formed when IXICO Ltd and Phytopharm PLC merged, said Friday that it believes it is strongly positioned in its core clinical trials and experimental medicine markets following the transition of its business.
The company formally known as Phytopharm acquired IXICO in September 2013. After the completion of this acquisition, it launched its CE-marked Assessa diagnostic platform with a partner and continued the commercialisation of its products and services in Asia.
The company said its core clinical trials and experimental medicine business continued to generate ongoing revenues from its key customers, and has been awarded contracts with four new customers post acquisition.
Ixico said it had now been awarded contracts with nine pharmaceutical companies and two new Asia-based pharmaceutical customers.
"We are delighted to have completed this major strategic evolution for the group and look forward with optimism and enthusiasm," said Chairman Andy Richards in a statement. "The launch of Assessa is an important landmark in IXICO's corporate history, and we look forward to updating shareholders on its progress as we develop international markets for it."
Shares in IXICO were trading up 5.1% at 65.00 pence Friday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Ixico